Systemic lupus erythematosus (SLE)
Maria Dall'Era, MD (she/her/hers)
Director
UCSF
Corte Madera, CA, United States
Disclosure(s): Annexon Biosciences: Consultant (Ongoing), Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing); Aurinia: Consultant (Ongoing); Biogen: Consultant (Ongoing); GlaxoSmithKlein: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing)
Richard Furie, MD
Chief of the Division of Rheumatology
Northwell Health
Manhasset, NY, NY, United States
Disclosure(s): Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing)
Marta Mosca, MD, PhD
University of Pisa
Pisa, Pisa, Italy
Disclosure(s): AstraZeneca: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Otsuka: Consultant (Ongoing); UCB: Consultant (Ongoing)
This Meet the Panel session will describe an approach to difficult cases in lupus, including the approach to difficult diagnostic conundrums in lupus, and will also describe the role of advanced therapeutics in lupus. This session will cover the practical use of recently approved medications for systemic lupus erythematosus and lupus nephritis.
Panelist: Maria Dall'Era, MD (she/her/hers) – UCSF
Panelist: Richard Furie, MD – Northwell Health
Panelist: Marta Mosca, MD, PhD – University of Pisa